Drugmakers blame middlemen known as pharmacy benefit managers for high drug prices. PBMs negotiate drug prices and rebates ...

One exception that enjoys bipartisan support, however, is the effort to rehab the drug supply chain. It’s currently dominated ...

Huge health conglomerates have another reason to worry that their business model might be disrupted. On a visit to Columbus Monday, one of the country’s top antitrust watchdogs said her agency is ...

By taking steps to hold middlemen ... Affordable Insulin Now Act moves towards the US Senate. Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi ...

No matter what happens in this election, the government should work for the people. The government may not be perfect, but it ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...